The Centers for Medicare and Medicaid Services finalized its decision to limit the coverage of Alzheimer’s drug Aduhelm and future monoclonal antibodies. In February…
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…
Two large hospitals, Cleveland Clinic and Mount Sinai, have decided against administering Aduhelm for patients following controversy around the Alzheimer’s drug’s FDA approval drug…
Will Medicare cover Alzheimer’s drugs like Aduhelm? That decision-making process is underway. This week, the U.S. government embarked on the formal review process to…
Image: Aduhelm, Biogen/AP. The head of the FDA, Dr. Janet Woodcock, calls for investigation into the agency’s own controversial approval of Biogen’s Aduhelm, the…
Following sharp criticisms of the FDA’s broad approval of Aduhelm for all patients with Alzheimer’s, the agency has narrowed the drug’s label to those…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…